References
- ChughSSHavmoellerRNarayananKWorldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 StudyCirculation2014129883784724345399
- WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
- KirleyKQatoDMKornfieldRStaffordRSAlexanderGCNational trends in oral anticoagulant use in the United States, 2007 to 2011Circ Cardiovasc Qual Outcomes20125561562122949490
- HellwigTGulsethMNew oral therapies for the prevention and treatment of venous thromboembolismAm J Health Syst Pharm201370211312523292264
- DobeshPPEconomic burden of venous thromboembolism in hospitalized patientsPharmacotherapy200929894395319637948
- Office of the Surgeon GeneralThe Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary EmbolismRockville, MDOffice of the Surgeon General2008 Available from: http://www.ncbi.nlm.nih.gov/books/NBK44178/
- MuellerRLScheidtSHistory of drugs for thrombotic disease. Discovery, development, and directions for the futureCirculation19948914324498281678
- AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGAmerican College of Chest PhysiciansOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple44Se88S22315269
- YouJJSingerDEHowardPAAmerican College of Chest PhysiciansAntithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple531Se575S22315271
- KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest2016149231535226867832
- HolbrookASchulmanSWittDMAmerican College of Chest PhysiciansEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple152Se184S22315259
- GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
- ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
- InvestigatorsEBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
- JanuaryCTWannLSAlpertJSAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
- HuangCSiuMVuLWongSShinJFactors influencing doctors’ selection of dabigatran in non-valvular atrial fibrillationJ Eval Clin Pract201319593894322834964
- CarleyBGriesbachSLarsonTKruegerKAssessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice settingAm J Cardiol2014113465065424484861
- LarockASMullierFSennesaelALAppropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective studyAnn Pharmacother201448101258126824982310
- SpinewineASwineCDhillonSEffect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trialJ Am Geriatri Soc2007555658665
- SpinewineADumontCMalletLSwineCMedication appropriateness index: reliability and recommendations for future useJ Am Geriatr Soc200654472072216686895
- Eliquis [package insert]Princeton, NJBristol-Myers Squibb Company2016
- Pradaxa [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2015
- Xarelto [package insert]Titusville, NJJanssen Pharmaceuticals, Inc2016
- KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther200578441242116198660
- NguyenEWhiteCMPatelMRDoses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trialsCurr Med Res Opin20163271277127927009372